Proteasome inhibitors: situation and prospects (literature review and own data)
https://doi.org/10.17650/1818-8346-2016-11-3-86-89
Abstract
Multiple myeloma is a clonal B-cell malignancy characterized by proliferation of plasma cells that accumulate mainly in bone marrow and usually secrete monoclonal Ig and/or Ig light chains. The history of therapy development in this disease has more than 50 years. After ubiquitin-proteasome system of apoptosis become apparent bortezomib has been included in the mains therapy regimes. Simultaneously, the group of proteasome-inhibitor drugs is continually developing and opening more therapeutic options in refractory or relapse forms.
About the Authors
A. A. Rukavitsyn
N.N. Burdenko Main Military Clinical Hospital, Ministry of Defense of Russia
Russian Federation
Russian Federation
O. A. Rukavitsyn
N.N. Burdenko Main Military Clinical Hospital, Ministry of Defense of Russia
Russian Federation
Russian Federation
References
1. Рукавицын О. А. Гематология. Национальное руководство. 2015. С. 565–573, 751. [Rukavitsyn O. A. Hematology. National guidelines. 2015. Pp. 565–573, 751. (In Russ.)].
2. Войцеховский В. В., Ландышев Ю. С. Множественная миелома, современные принципы диагностики и лечения. Минздравсоцразвития РФ, ГБОУ ВПО «Амурская государственная медицинская академия», 2012. С. 74–77. [Voytsekhovskiy V. V., Lahdyshev Yu. S. Multiple myeloma, current principles of diagnosis and treatment. Ministry of Health of Russian Federation, Amur State Medical Academy, 2012. Pp. 74–77. (In Russ.)].
3. Richardson P. G., Sonneveld P., Schuster M. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110(10):557– 3560. DOI: 10.1182/blood-2006-08-036947.
4. San-Miguel J. F., Richardson P. G., Sonneveld P. et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008;22(4):842–9. DOI: 10.1038/sj.leu.2405087.
5. Richardson P. G., Xie W., Mitsiades C. et al. Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. J Clin Oncol 2009;27(21):3518–25. DOI: 10.1200/JCO.2008.18.3087.
6. Vij R., Siegel D. S., Jagannath S. et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158(6):739–48. DOI: 10.1111/j.1365-2141.2012.09232.x.
7. Siegel D., Martin T., Nooka A. et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98(11):1753–61. DOI: 10.3324/haematol.2013.089334.
8. Avet-Loiseau H., Fonseca R., Siegel D. et al. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood 2016;128(9):1174–80. DOI: 10.1182/blood-2016-03-707596.
9. Ludwig H., Greil R., Masszi T. et al. Bortezomib, thalidomide and dexamethasone, with or without cyclo phosphamide, for patients with previously untreated multiple myeloma: 5-year followup. Br J Haematol 2015;171(3):344–54. DOI: 10.1111/bjh.13582.
10. Stewart A. K., Rajkumar S. V., Dimopoulos M. A. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142–52. DOI: 10.1056/NEJMoa1411321.
11. Kumar S. K., LaPlant B., Roy V. et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015;5:e338. DOI: 10.1038/bcj.2015.60.
12. Moreau P., Masszi T., Grzasko N., Bahlis N. J. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621–34. DOI: 10.1056/NEJMoa1516282.
13. Kumar S. K., Bensinger W. I., Zimmerman T. M. et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 2014;124(7):1047–55. DOI: 10.1182/blood-2014-01-548941.
14. Rajan A. M., Kumar S. New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J 2016;6(7):e451. DOI: 10.1038/bcj.2016.53.
15. Dimopoulos M. A., Beksac M., Benboubker L. et al. Phase II study of bortezomib – dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013;98(8):1264–72. DOI: 10.3324/haematol.2013.084376.
Review
For citations:
Rukavitsyn A.A., Rukavitsyn O.A. Proteasome inhibitors: situation and prospects (literature review and own data). Oncohematology. 2016;11(3):86-89. (In Russ.) https://doi.org/10.17650/1818-8346-2016-11-3-86-89
Views:
10430
Email this article 